In this issue:
Canadian guidelines recommended COVID vaccination for patients with autoimmune rheumatic diseases
Impaired exercise capacity in axSpA increases risk for cardiovascular disease
Secukinumab efficacious for achievement of clinically relevant higher-hurdle endpoints
Comparable treatment retention and response to secukinumab versus TNF inhibitors
Nordic cohort study finds no increased risk of malignancy in anti-TNF exposed patients
Biologic DMARDs confer a four-times increased risk of serious infection
Bridging the gap between symptom onset and diagnosis in axSpA
Australian patients’ perspectives on shared decision-making about medications
Analgesic use is common in PsA but reduced by biologic agent initiation
COVID-19 and autoinflammatory diseases
Please login below to download this issue (PDF)